Data Availability
The data supporting this study’s findings are available from the corresponding author (SP) upon reasonable request.
Funding
The study was funded by Fondazione Italiana Malattie Pancreas (FIMP), Italian Ministry of Health (CUP_J38D19000690001). Fabio Casciani was supported by Fondazione Umberto Veronesi.
Author information
Authors and Affiliations
Contributions
Conceptualization: SP, GM, CB, RS. Data curation: SP, AC, FC, MDP, GL, ES. Formal Analysis: SP, FC, MDP, GL, ES. Funding acquisition: CB, FC. Investigation: SP, GM. Methodology: SP, GM. Project administration: SP, RS, CB. Resources: SP, GM, RS. Supervision: RS, CB. Validation: SP, GM, CB, RS. Visualization: SP, GM, ES. Writing – original draft: All authors Writing – review & editing: All Authors.
Corresponding authors
Ethics declarations
Disclosure
Salvatore Paiella receives consultancy honoraria from AlphaTau. The remaining authors have no conflicts of interest.<AQ3>
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Presented in part at the 2023 Annual Pancreas Club Meeting, Chicago, USA, May 2023, at the Digestive Disease Week Annual Meeting, Chicago, May 2023, and at the EAHPBA 2023 Meeting, at Lyon, France, June 2023.
Rights and permissions
About this article
Cite this article
Paiella, S., Malleo, G., Lionetto, G. et al. ASO Visual Abstract: Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use—A Prospective Real-Life Study. Ann Surg Oncol 31, 2977–2978 (2024). https://doi.org/10.1245/s10434-024-15024-2
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-15024-2